Improving Treatments - Improving Lives

Veloxis Pharmaceuticals (Veloxis) is a speciality pharmaceutical company focused on the development and commercialization of Envarsus® (LCP-Tacro) for the prevention of organ rejection in kidney transplant patients. All clinical studies for Envarsus®, including two Phase III trials, have successfully been completed and a New Drug Application (NDA) was submitted to the U.S. Food and Drug Administration (FDA) in December 2013 seeking approval for the marketing and sale of Envarsus®. Envarsus® has been granted Orphan Drug Status by the FDA.


Efforts to Obtain FDA Approval

Nov 13, 2014
Presentation of the Interim Report for the 3rd Quarter 2014

Webcast Q3 2014 Audiocast
PDF Q3 2014 Interim Report
 760.2 KB   Add to Briefcase
PDF Q3 2014 Presentation
 379.0 KB   Add to Briefcase




Stock Information